Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as ...

PLT012, a groundbreaking anti-CD36 antibody, enters clinical trials to enhance immune responses in solid tumors, promising ...

Scientists have identified a promising strategy to improve liver cancer immunotherapy: targeting B-cells. While immunotherapy ...

While new late-stage data point to some liver toxicity signals, analysts at BMO Capital Markets said Tukysa’s efficacy ...

The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) plus Akeega (abiraterone acetate) and prednisone ...

The FDA's fast track designation acknowledges the combination's promising early efficacy and safety profile in treating MSS mCRC. Early data from a phase 1b/2 study showed deep, durable responses with ...

Recurrent or metastatic nasopharyngeal carcinoma is an aggressive disease, and long-term survival with chemotherapy alone is ...

Ragnhild Langli (70) is the first person in Norway to receive personalized chemotherapy for bowel cancer. She is ...

Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by BC ...

CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by ...

My best advice for anyone recently diagnosed with MBC is to keep a notebook and take someone with you to every appointment.

SABCS 2025 analysis shows persistent racial and socioeconomic gaps in metastatic HR+/HER2 negative breast cancer diagnosis ...